A Phase I, Open Label, Study of the Safety and Tolerability of KU-0059436 and Dacarbazine in the Treatment of Patients With Advanced Solid Tumours

Inclusion Criteria:

- Patients must have:

1. Unresectable stage 3 or stage 4 cutaneous melanoma or unknown primary melanoma
with metastases.

2. Histological or cytological confirmation of melanoma. Histological confirmation
of melanoma from the primary site will suffice, unless the primary site is
unknown.

Exclusion Criteria:

- Previous treatment with cytotoxic chemotherapy for advanced melanoma, apart from
treatment for melanoma with isolated limb perfusion.

- Radiotherapy (except for palliative reasons), endocrine therapy, immunotherapy or use
of other investigational agents within 4 weeks prior to trial entry (or a longer
period depending on the defined characteristics of the agents used).

- Major surgery within 4 weeks of starting the study.